Nevro (NYSE:NVRO – Get Rating) had its target price lowered by Piper Sandler from $45.00 to $42.00 in a research note issued to investors on Thursday morning, The Fly reports. Piper Sandler currently has a neutral rating on the medical equipment provider’s stock.
Other equities analysts also recently issued reports about the company. Jefferies Financial Group assumed coverage on Nevro in a research report on Wednesday, October 12th. They issued an underperform rating and a $31.00 target price for the company. Truist Financial lowered their price objective on Nevro to $45.00 in a research report on Friday, July 22nd. Morgan Stanley lowered their price objective on Nevro from $54.00 to $49.00 and set an equal weight rating for the company in a research report on Tuesday, October 11th. Wells Fargo & Company lowered their price objective on Nevro from $90.00 to $86.00 and set an overweight rating for the company in a research report on Thursday, August 4th. Finally, StockNews.com initiated coverage on Nevro in a research report on Wednesday, October 12th. They set a hold rating for the company. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Hold and an average price target of $64.50.
Nevro Price Performance
Nevro stock opened at $40.75 on Thursday. The company has a current ratio of 7.05, a quick ratio of 5.36 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $1.44 billion, a PE ratio of -123.48 and a beta of 0.75. Nevro has a 12 month low of $34.70 and a 12 month high of $114.10. The stock has a 50-day moving average price of $43.43 and a two-hundred day moving average price of $46.37.
Institutional Investors Weigh In On Nevro
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems.
- Get a free copy of the StockNews.com research report on Nevro (NVRO)
- Edwards Life Sciences Stock Disaster Could Be Your Bounty
- It Not All Bad News for Advanced Micro Devices Stock
- After Doubling, First Solar May Keep Shining
- Barrick Gold is a Hold as Long as Gold Prices Stay Stagnant
- MarketBeat: Week in Review 10/31-11/4
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.